上海医药:盐酸坦索罗辛原料药获批上市 研发投入150万元

财中社
Feb 11

  2月11日,上海医药(601607/02607)发布公告,旗下公司上药康丽收到国家药监局颁发的盐酸坦索罗辛原料药上市申请批准通知书,标志该药物获得生产许可。

  盐酸坦索罗辛是一种第三代超选择性长效α1抑制剂,主要用于治疗良性前列腺增生症。公司为该药物的研发已投入约150万元。公告提到,2024年中国大陆医院采购盐酸坦索罗辛制剂的金额为4.14亿元。

  尽管此次批准有助于公司在国内市场的销售,但因受国家政策和市场环境等不确定因素影响,该药物的销售可能存在不达预期的风险,投资者需谨慎决策。

  2025年前三季度,上海医药实现收入2150.72亿元,归母净利润51.47亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10